Empirical Financial Services LLC d.b.a. Empirical Wealth Management Raises Position in Hologic, Inc. (NASDAQ:HOLX)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 11.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,427 shares of the medical equipment provider’s stock after purchasing an additional 6,986 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Hologic were worth $4,933,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Wolff Wiese Magana LLC purchased a new stake in Hologic in the third quarter worth about $25,000. General Partner Inc. bought a new position in shares of Hologic during the 4th quarter valued at approximately $26,000. Groupama Asset Managment increased its holdings in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in Hologic during the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

Hologic stock opened at $71.02 on Monday. The company’s 50-day moving average price is $74.01 and its 200-day moving average price is $78.27. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $16.03 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.43 and a beta of 0.97. Hologic, Inc. has a twelve month low of $68.61 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.89 earnings per share. On average, equities research analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Monday, January 13th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and cut their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, Raymond James boosted their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.